General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, Placebo-Controlled Trials

Francis Berenbaum, Thomas J Schnitzer, Alan J Kivitz, Lars Viktrup, Anne Hickman, Glenn Pixton, Mark T Brown, Isabelle Davignon, Christine R West, Francis Berenbaum, Thomas J Schnitzer, Alan J Kivitz, Lars Viktrup, Anne Hickman, Glenn Pixton, Mark T Brown, Isabelle Davignon, Christine R West

Abstract

Objective: This pooled analysis of 3 randomized, placebo-controlled trials (16-24 week treatment and 8-24 week follow-up) assessed safety of subcutaneous tanezumab (2.5-10 mg every 8 weeks) in 1,840 patients with hip or knee osteoarthritis.

Methods: Overall treatment-emergent adverse events (TEAEs) and TEAEs of abnormal peripheral sensation (APS) were prospectively assessed in 3 trials. Joint safety events (primary osteonecrosis, rapidly progressive osteoarthritis [RPOA], subchondral insufficiency fracture, and pathologic fracture; adjudicated by an independent expert committee) and TEAEs potentially associated with sympathetic neuropathy were prospectively assessed in 2 trials.

Results: During the treatment period, overall TEAE rates were 51.7% for placebo and 39.5-54.8% for tanezumab 2.5-10 mg; treatment discontinuation rates were 2.0% for placebo and 0-1.3% for tanezumab. Rates of composite joint safety events (predominantly RPOA type 1) over the treatment plus follow-up period were 0% for placebo and 0.5-3.2% for tanezumab 2.5-5 mg (5 mg was statistically greater than placebo); total joint replacement rates with tanezumab (5.9-7.0%) were not significantly different from placebo (4.5%). Rates of TEAEs of APS (predominantly paresthesia and hypoesthesia) were 2.2% for placebo and 3.2-12.8% for tanezumab 2.5-10 mg. Rates of TEAEs potentially associated with sympathetic neuropathy (predominantly bradycardia and orthostatic hypotension) were 0.8% for placebo and 0.5-2.8% for tanezumab 2.5-5 mg (exposure-adjusted rates were not significantly different from placebo).

Conclusion: Tanezumab was generally well tolerated. TEAEs of APS (mostly mild and transient) and joint safety events were infrequent but more common with tanezumab than placebo. A tanezumab dose of 2.5 mg demonstrated a more favorable safety profile than higher doses.

Trial registration: ClinicalTrials.gov NCT01089725 NCT02697773 NCT02709486.

© 2021 Pfizer Inc. Arthritis Care & Research published by Wiley Periodicals LLC on behalf of American College of Rheumatology.

References

    1. Hefti F. Pharmacology of nerve growth factor and discovery of tanezumab, an anti‐nerve growth factor antibody and pain therapeutic. Pharmacol Res 2020;154:104240.
    1. Schnitzer TJ, Ekman EF, Spierings EL, Greenberg HS, Smith MD, Brown MT, et al. Efficacy and safety of tanezumab monotherapy or combined with non‐steroidal anti‐inflammatory drugs in the treatment of knee or hip osteoarthritis pain. Ann Rheum Dis 2015;74:1202–11.
    1. Ekman EF, Gimbel JS, Bello AE, Smith MD, Keller DS, Annis KM, et al. Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen. J Rheumatol 2014;41:2249–59.
    1. Balanescu AR, Feist E, Wolfram G, Davignon I, Smith MD, Brown MT, et al. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double‐blind, placebo‐controlled, parallel‐group, multicentre phase III randomised clinical trial. Ann Rheum Dis 2014;73:1665–72.
    1. Spierings EL, Fidelholtz J, Wolfram G, Smith MD, Brown MT, West CR. A phase III placebo‐ and oxycodone‐controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee. Pain 2013;154:1603–12.
    1. Brown MT, Murphy FT, Radin DM, Davignon I, Smith MD, West CR. Tanezumab reduces osteoarthritic hip pain: results of a randomized, double‐blind, placebo‐controlled phase III trial. Arthritis Rheum 2013;65:1795–803.
    1. Brown MT, Murphy FT, Radin DM, Davignon I, Smith MD, West CR. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double‐blind, placebo‐controlled phase III trial. J Pain 2012;13:790–8.
    1. Schnitzer TJ, Lane NE, Birbara C, Smith MD, Simpson SL, Brown MT. Long‐term open‐label study of tanezumab for moderate to severe osteoarthritic knee pain. Osteoarthritis Cartilage 2011;19:639–46.
    1. Lane NE, Schnitzer TJ, Birbara CA, Mokhtarani M, Shelton DL, Smith MD, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 2010;363:1521–31.
    1. Hochberg MC, Tive LA, Abramson SB, Vignon E, Verburg KM, West CR, et al. When is osteonecrosis not osteonecrosis? Adjudication of reported serious adverse joint events in the tanezumab clinical development program. Arthritis Rheumatol 2016;68:382–91.
    1. Tive L, Bello AE, Radin D, Schnitzer TJ, Nguyen H, Brown MT, et al. Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip. J Pain Res 2019;12:975–95.
    1. Brown MT, Herrmann DN, Goldstein M, Burr AM, Smith MD, West CR, et al. Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment. J Neurol Sci 2014;345:139–47.
    1. Schnitzer TJ, Easton R, Pang S, Levinson DJ, Pixton G, Viktrup L, et al. Effect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee: a randomized clinical trial. JAMA 2019;322:37–48.
    1. Berenbaum F, Blanco FJ, Guermazi A, Miki K, Yamabe T, Viktrup L, et al. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24‐week randomised phase III study with a 24‐week follow‐up period. Ann Rheum Dis 2020;79:800–10.
    1. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833–40.
    1. Miller CG, Guermazi A, Roemer F. The current status of imaging in anti‐NGF clinical trials. Osteoarthritis Cartilage 2015;23 Suppl 1:S3–7.
    1. Zilliox L, Peltier AC, Wren PA, Anderson A, Smith AG, Singleton JR, et al. Assessing autonomic dysfunction in early diabetic neuropathy: the Survey of Autonomic Symptoms. Neurology 2011;76:1099–105.
    1. Gropp KE, Carlson CS, Evans MG, Bagi CM, Reagan WJ, Hurst SI, et al. Effects of monoclonal antibodies against nerve growth factor on healthy bone and joint tissues in mice, rats, and monkeys: histopathologic, biomarker, and microcomputed tomographic assessments. Toxicol Pathol 2018;46:408–20.
    1. Xu L, Nwosu LN, Burston JJ, Millns PJ, Sagar DR, Mapp PI, et al. The anti‐NGF antibody muMab 911 both prevents and reverses pain behaviour and subchondral osteoclast numbers in a rat model of osteoarthritis pain. Osteoarthritis Cartilage 2016;24:1587–95.
    1. LaBranche TP, Bendele AM, Omura BC, Gropp KE, Hurst SI, Bagi CM, et al. Nerve growth factor inhibition with tanezumab influences weight‐bearing and subsequent cartilage damage in the rat medial meniscal tear model. Ann Rheum Dis 2017;76:295–302.
    1. Schmelz M, Mantyh P, Malfait AM, Farrar J, Yaksh T, Tive L, et al. Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low‐back pain: mechanism of action in the context of efficacy and safety. Pain 2019;160:2210–20.
    1. Hochberg MC, Carrino JA, Schnitzer TJ, Guermazi A, Walsh DA, White A, et al. Long‐term safety and efficacy of subcutaneous tanezumab versus nonsteroidal antiinflammatory drugs for hip or knee osteoarthritis: a randomized trial. Arthritis Rheumatol 2021;73:1167–77.
    1. Barker PA, Mantyh P, Arendt‐Nielsen L, Viktrup L, Tive L. Nerve growth factor signaling and its contribution to pain. J Pain Res 2020;13:1223–41.
    1. Bannwarth B, Kostine M. Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists? Drugs 2014;74:619–26.
    1. Bramson C, Herrmann DN, Carey W, Keller D, Brown MT, West CR, et al. Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain. Pain Med 2015;16:1163–76.
    1. Brown M, Koltzenburg M, Nguyen H, West C, Verburg K. Tanezumab does not cause sympathetic nervous system dysfunction in clinical osteoarthritis studies (P3.303). Neurology 2015;84: Suppl.
    1. Belanger P, Butler P, Butt M, Bhatt S, Foote S, Shelton D, et al. Evaluation of the effects of tanezumab, a monoclonal antibody against nerve growth factor, on the sympathetic nervous system in adult cynomolgus monkeys (Macaca fascicularis): a stereologic, histomorphologic, and cardiofunctional assessment. Toxicol Sci 2017;158:319–33.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner